Loading stock data…
$72.32+1.50 (+2.12%)
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $72.32 with a market capitalization of $4.0B. Wall Street consensus targets $99.80 (10 analysts), implying a +38.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $91.53, remaining 6.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $173.91M↑ | $162.05M↑ | $151.67M↑ | $118.70M↑ | $102.66M |
| Gross Profit | $161.80M↑ | $152.66M↑ | $140.74M↑ | $110.39M↑ | $96.42M |
| Operating Income | -$19.91M↓ | -$6.12M↑ | -$7.98M↑ | -$14.53M↑ | -$22.18M |
| Net Income | -$18.55M↓ | -$6.97M↑ | -$8.37M↑ | -$12.59M↑ | -$20.34M |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...